impact factor
logo
 

Full Papers

 

Post-hoc analysis of pegloticase pivotal trials in chronic refractory gout: relationship between fluctuations in plasma urate levels and acute flares


1, 2, 3, 4, 5

 

  1. Department of Rheumatologic and Immunologic Disease, Cleveland Clinic, Cleveland, OH, USA.
  2. Division of Rheumatology, Hospital for Special Surgery, New York, NY, USA.
  3. Department of Medicine, Division of Rheumatology, Immunology and Allergy, University of Florida, Gainesville, FL, USA.
  4. Yeo Analytics, LLC, Jersey City, NJ, USA.
  5. AMPEL BioSolutions, LLC, Charlottesville, VA, USA. peterlipsky@comcast.net

CER13812
2021 Vol.39, N°5
PI 1085, PF 1092
Full Papers

purchase article

PMID: 33427618 [PubMed]

Received: 14/07/2020
Accepted : 28/09/2020
In Press: 06/01/2021
Published: 31/08/2021

Abstract

OBJECTIVES:
To determine factors associated with gout flares in subjects treated with pegloticase.
METHODS:
Gout flares from two randomised controlled trials comparing pegloticase (8 mg every 2 weeks [q2] or monthly [q4]) versus placebo were analysed. Responders had persistent urate lowering (<6mg/dL) whereas, non-responders had transient urate lowering during the 6-month RCTs. Gout flares (self-reported) were defined as acute joint pain and swelling requiring treatment. Gout flare prophylaxis (colchicine, 0.6 mg once or twice daily, or a non-steroidal anti-inflammatory drug) was initiated 1 week before the first infusion and continued throughout the study. Plasma urate at the time of flare and the change in urate preceding a flare were analysed.
RESULTS:
Mean flare rates increased with pegloticase versus placebo during the first 3 months followed by marked reductions during months 4–6. The increase in flares with pegloticase during the first 3 months was most evident (p=0.0006) and the decrease during the second 3 months was least marked (p=0.0006) in subjects receiving monthly pegloticase. Fluctuation in urate levels was highest in monthly responders (p=0.002) and was associated with flare occurrence. Multivariate linear regression analysis indicated the only variables significantly associated with flares were treatment group and absolute change in plasma urate before flares.
CONCLUSIONS:
Pegloticase treatment increased flares during the first 3 months of treatment in all groups when plasma urate was significantly lowered and was followed by a decline in months 4-6 in patients maintaining a low plasma urate. Flares associated with pegloticase treatment were associated with decreases and fluctuations in plasma urate levels.

Rheumatology Article